Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

• Market Cap: $59.64M
• Dividend Yield: N/A
• Average Volume (3M): 996.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: 21.17%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 31,555,126
• 10 Day Avg. Volume: 442,853
• 30 Day Avg. Volume: 996,436
• PEG Ratio: 0.12
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -22.16
• Enterprise Value/Ebitda: -0.33
• 1Y Price Target: $10.50
• Price Target Upside: 458.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $2.00 ▲(6.38% Upside)

The score is held down primarily by weak financial performance—no revenue, large and persistent losses, and substantial cash burn—despite low leverage. Technicals remain soft with the stock below key short- and mid-term moving averages, while valuation support is limited due to losses and no dividend. Offsetting these risks, recent positive clinical data and pipeline progress modestly improve the outlook.

Positive Factors

Biomarker‑driven clinical efficacy

Robust biomarker-selected Phase 2b responses (39% ORR) materially improve the likelihood of a registrational pathway and more efficient trial designs. Over 2–6 months this strengthens the program’s development odds, competitive differentiation, and prospects for targeted patient approval.

Diversified pipeline and platform

Signals from ACR-2316 plus nomination of ACR-6840 with an IND planned for late 2026 show multiple development candidates built on the AP3 platform. This durable diversification reduces single‑asset risk and supports a platform-driven franchise strategy and partnership appeal.

Low financial leverage

Very low debt relative to equity (debt-to-equity ~0.02) limits near-term solvency risk and preserves flexibility for clinical development. Over coming months this lowers default risk and provides optionality for capital raises or licensing without acute leverage constraints.

Negative Factors

No revenue and widening losses

Acrivon remains a clinical‑stage company with no operating revenue and materially wider losses (~$80M annually). Structurally this necessitates ongoing financing, increases dilution risk, and constrains strategic choices and reinvestment capacity across the development portfolio.

High cash burn

Operating cash flow and free cash flow are deeply negative (~-$66M TTM), reflecting accelerating burn. This durable pressure shortens runway for registrational activities, making the company dependent on external capital and potentially delaying trials or forcing unfavorable financing terms.

Erosion of shareholder equity

Shareholders' equity has fallen meaningfully year‑over‑year, indicating net worth erosion from cumulative losses. Over the medium term this reduces financial cushions, raises perceived financing need, and increases the likelihood and potential cost of future dilutive capital raises.

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

How the Company Makes Money

Acrivon Therapeutics, Inc. makes money primarily through the development and commercialization of its targeted oncology therapies. The company generates revenue by advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval and subsequently marketing these therapies. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and milestone payments upon achieving specific clinical and regulatory milestones. Additionally, Acrivon may engage in collaborative research and development agreements to enhance its pipeline and broaden its market reach.

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary

Clinical-stage profile with no revenue and widening losses (net loss ~-$80.6M in 2024; ~-$81.8M TTM) alongside heavy cash burn (operating cash flow ~-$65.8M TTM; FCF ~-$68.1M TTM). Balance sheet leverage is low (debt ~ $3.0M vs. equity ~$128.6M; debt-to-equity ~0.02), but equity is declining due to ongoing losses, increasing financing/dilution risk.

Income Statement

Across annual periods (2020–2024) and TTM (Trailing-Twelve-Months) 2025-09-30, the company reports no revenue and sustained operating losses, consistent with a clinical-stage biotech profile. Losses have widened materially versus 2022 (net loss of about $31.2M) to 2024 (about $80.6M) and remain elevated in TTM (Trailing-Twelve-Months) (about $81.8M), indicating rising spend without offsetting commercial revenue. The key strength is cost flexibility typical of R&D-stage companies, but the primary weakness is the absence of revenue and a deep, persistent loss profile that will likely require ongoing funding.

Balance Sheet

The balance sheet shows low leverage, with total debt of roughly $3.0M in TTM (Trailing-Twelve-Months) against stockholders’ equity of about $128.6M (debt-to-equity ~0.02), which reduces solvency risk near term. Total assets are about $145.3M in TTM (Trailing-Twelve-Months). However, equity has declined from 2024 (~$176.8M) to TTM (Trailing-Twelve-Months) (~$128.6M), reflecting continued losses and cash burn, and return on equity is meaningfully negative in recent periods (TTM roughly -0.54). Overall: strong capital structure (low debt) but weakening net worth trajectory due to ongoing losses.

Cash Flow

Cash generation remains a clear pressure point: operating cash flow is deeply negative and has scaled up from about -$30.1M (2022) to about -$65.7M (2024) and remains about -$65.8M in TTM (Trailing-Twelve-Months). Free cash flow is also negative (TTM roughly -$68.1M), and the provided free cash flow growth metric is negative in recent periods, indicating worsening burn rather than improving efficiency. A relative positive is that free cash flow broadly tracks net loss (free cash flow to net income ~1.03–1.07 historically), suggesting losses are not dramatically understating cash usage—but the absolute cash burn level remains high.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.21M	-1.01M	-536.00K	0.00	0.00	-13.00K
EBITDA	-80.54M	-79.55M	-59.85M	-32.29M	-16.15M	-5.29M
Net Income	-81.75M	-80.56M	-60.39M	-31.17M	-16.24M	-5.31M
Balance Sheet
Total Assets	145.30M	196.59M	138.26M	181.23M	106.59M	2.19M
Cash, Cash Equivalents and Short-Term Investments	129.25M	179.48M	127.46M	127.75M	99.60M	1.58M
Total Debt	2.99M	3.65M	4.64M	4.96M	5.63M	58.00K
Total Liabilities	16.70M	19.80M	17.07M	10.75M	130.40M	10.60M
Stockholders Equity	128.60M	176.79M	121.19M	170.47M	-23.81M	-8.41M
Cash Flow
Free Cash Flow	-68.06M	-68.44M	-43.93M	-32.28M	-14.22M	-2.82M
Operating Cash Flow	-65.79M	-65.67M	-42.64M	-30.12M	-13.98M	-2.80M
Investing Cash Flow	58.99M	-51.77M	50.72M	-141.68M	-238.00K	-15.00K
Financing Cash Flow	-1.20M	121.03M	-1.55M	101.71M	112.22M	2.89M

Acrivon Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Negative. The current price of 1.88 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.26, and above the 200-day MA of 1.70, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.88 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRV.

Acrivon Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$59.64M	-0.88	-50.23%	―	―	21.17%
CAMP	49 Neutral	$207.52M	-1.58	-172.70%	―	―	5.51%
ALGS	42 Neutral	$49.60M	-0.41	-141.82%	―	-55.88%	6.14%

Acrivon Therapeutics, Inc. Corporate Events

Acrivon Showcases Promising Phase 2b Oncology Data Update

On January 8, 2026, Acrivon Therapeutics hosted a corporate webcast and conference call to present updated clinical data for its lead oncology programs ACR-368 and ACR-2316, alongside broader AP3 pipeline developments. The company highlighted Phase 2b data from its ACR-368-201 (GOG-3082) trial in endometrial cancer, including an overall response rate of 39% for ACR-368 monotherapy in OncoSignature-positive patients and 26% for the ACR-368 plus ultra-low-dose gemcitabine combination, as well as particularly strong responses in biomarker-selected and serous endometrial cancer subgroups; these results, derived from non–QC’ed data as of December 4, 2025, support ACR-368’s registrational-intent pathway and reinforce Acrivon’s biomarker-driven strategy in a tumor type with significant unmet need, potentially strengthening its competitive positioning in precision oncology.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data

On January 8, 2026, Acrivon Therapeutics reported updated Phase 2b data for its CHK1/CHK2 inhibitor ACR-368 in endometrial cancer, with an interim analysis as of December 4, 2025 showing a 39% overall response rate in biomarker-positive monotherapy patients and a 44% rate in those with two or fewer prior lines of therapy; in the serous endometrial cancer subtype, confirmed response rates reached 67% in biomarker-positive patients and 52% across biomarker-positive and -negative subjects, prompting the company to refocus Arm 3 of the trial on serous patients with limited prior treatment and to expand this arm into more than 20 trial sites across Germany, Italy, France and Spain, with EU enrollment expected to begin in the first quarter of 2026 and overall Arm 3 enrollment completion targeted for the fourth quarter of 2026. The company also detailed progress in its broader pipeline, including initial Phase 1 results for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, where 33 patients treated as of December 22, 2025 showed favorable tolerability and tumor shrinkage in 9 of 20 evaluable subjects—including partial responses in endometrial cancer, small cell lung cancer and squamous non-small cell lung cancer—and the nomination of ACR-6840, an AP3-derived CDK11 inhibitor, as its next development candidate with an investigational new drug application planned for late 2026, underscoring Acrivon’s drive to build a differentiated, AP3-enabled precision oncology franchise.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.